Tomoya Murakami

Dr. Tomoya Murakami

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2021 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
TMTomoya Murakami
Tomoya Murakami
YSYoshimi Sugiura
Yoshimi Sugiura
FOFumiki Okamoto
Fumiki Okamoto
YOYoshifumi Okamoto
Yoshifumi Okamoto
AKAtsuko Kato
Atsuko Kato
TOTetsuro Oshika
Tetsuro Oshika

6 May 2023 in Eye
Verified
Journal Article
Open access
PDF file
TMTomoya Murakami
Tomoya Murakami
FOFumiki Okamoto
Fumiki Okamoto
TKTakamasa Kinoshita
Takamasa Kinoshita
KSKayo Shinomiya
Kayo Shinomiya
TNTomo Nishi
Tomo Nishi
TOTetsuro Oshika
Tetsuro Oshika
Objectives To compare real-world, long-term outcomes of laser and anti-vascular endothelial growth factor (VEGF) therapies in patients with retinopathy of prematurity (ROP). Methods This was a multicentre retrospective study. We included 264 eyes of 139 patients treated for type 1 ROP or aggressive ROP (AROP) who were followed for at least 4 years. Laser treatment was initially performed in 187 eyes (the laser group), and anti-VEGF therapy was initially performed in 77 eyes (the anti-VEGF group). We collected data on sex, birth characteristics, zone, stage, and the presence of plus disease at the time of treatment and best-corrected visual acuity (BCVA), spherical equivalent (SE), and ocular complications (amblyopia and strabismus) in patients aged 4–6 years. We investigated the associations between treatment outcomes (BCVA, SE and the presence of amblyopia and strabismus) and influencing factors, including treatment procedure (anti-VEGF or laser therapy), sex, birth characteristics, zone, stage, and the presence of plus disease, using multivariable analysis and logistic regression analyses. Results The initial treatment procedure was not associated with any specific treatment outcome. Subgroup analysis of patients with zone I ROP revealed that the anti-VEGF-treated eyes had significantly better BCVA and higher SE than laser-treated eyes (p = 0.004, p = 0.009, respectively). Female patients presented significantly better BCVA, less amblyopia and less strabismus than male patients (p < 0.001, p = 0.029, p = 0.008, respectively). Conclusions In zone I ROP, anti-VEGF therapy led to better visual acuity and less myopic refractive error than laser treatment.

17 October 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TMTomoya Murakami
Tomoya Murakami
FOFumiki Okamoto
Fumiki Okamoto
YSYoshimi Sugiura
Yoshimi Sugiura
SMShohei Morikawa
Shohei Morikawa
YOYoshifumi Okamoto
Yoshifumi Okamoto
TOTetsuro Oshika
Tetsuro Oshika
The aim of the present study was to investigate changes in metamorphopsia in patients with diabetic macular edema (DME) following intravitreal aflibercept injection (IVA) with the treat and extend (TAE) regimen for a year. We performed a post hoc analysis of a multicenter, open-label, single-arm, prospective study. The study included 20 patients with DME. All eyes received 3 monthly loading injections of 2 mg aflibercept, followed by a TAE regimen. Every visit, the severity of metamorphopsia and the best-corrected visual acuity (BCVA) were evaluated, and optical coherence tomography (OCT) images were obtained. The severity of metamorphopsia was measured using M-CHARTS. The metamorphopsia scores before treatment and at 1, 2, 3, 6 and 12 months following treatment were 0.25 ± 0.23, 0.21 ± 0.15, 0.19 ± 0.23, 0.14 ± 0.16, 0.17 ± 0.20 and 0.10 ± 0.17, respectively, with significant improvement from before treatment to 3 and 12 months following treatment (p < 0.05 and p < 0.005, respectively). At the time of macular edema resolution, the presence of an epiretinal membrane (ERM) was associated with the metamorphopsia score (p < 0.05). In conclusion, the metamorphopsia score in patients with DME improved following IVA with the TAE regimen for one year. The presence of ERM was associated with the metamorphopsia score.

31 July 2022 in Experimental Eye Research
Verified
Journal Article
Closed access
TMTomoya Murakami
Tomoya Murakami
Sujin HoshiSujin Hoshi
Sujin Hoshi
FOFumiki Okamoto
Fumiki Okamoto
TSTakamasa Sakai
Takamasa Sakai
TKTakuya Katashima
Takuya Katashima
TOTetsuro Oshika
Tetsuro Oshika

15 February 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Fumiki OkamotoFumiki Okamoto
Fumiki Okamoto
TMTomoya Murakami
Tomoya Murakami
SMShohei Morikawa
Shohei Morikawa
YSYoshimi Sugiura
Yoshimi Sugiura
THTakahiro Hiraoka
Takahiro Hiraoka
TOTetsuro Oshika
Tetsuro Oshika
Even after successful surgery, the stereopsis of retinal detachment (RD) patients is inferior to that of normal subjects. However, it is unclear which visual dysfunction in the affected eye is responsible for the postoperative stereopsis impairment. This study included 127 patients after successful surgery for unilateral RD. Stereopsis, best-corrected visual acuity (BCVA), severity of metamorphopsia, letter contrast sensitivity and amount of aniseikonia were examined at 6-month postoperatively. Stereopsis was assessed using the Titmus Stereo Test (TST) and TNO stereotest (TNO). Postoperative stereopsis (log) in patients with RD were 2.09 ± 0.46 in the TST and 2.56 ± 0.62 in the TNO. Multivariate analysis with stepwise regression revealed postoperative TST was associated with BCVA, and TNO was associated with BCVA, letter contrast sensitivity, metamorphopsia and absolute values of aniseikonia. In a subgroup analysis that selected those with more impaired stereopsis, postoperative TST was associated with BCVA (p < 0.001), and TNO was associated with letter contrast sensitivity (p < 0.005) and absolute values of aniseikonia (p < 0.05) by multivariate analysis. Deterioration of stereopsis after RD surgery was affected by a variety of visual dysfunctions. The TST was affected by visual acuity, while the TNO was affected by contrast sensitivity and aniseikonia.

Verified
Journal Article
Open access
PDF file
TMTomoya Murakami
Tomoya Murakami
Fumiki OkamotoFumiki Okamoto
Fumiki Okamoto
YSYoshimi Sugiura
Yoshimi Sugiura
SMShohei Morikawa
Shohei Morikawa
YOYoshifumi Okamoto
Yoshifumi Okamoto
TOTetsuro Oshika
Tetsuro Oshika
Visual functions that affect vision-related quality of life (VR-QoL) before and after intravitreal injection of ranibizumab in patients with cystoid macular edema secondary to central retinal vein occlusion (CRVO-CME) are poorly understood. This multicenter, open-label, single-arm prospective study included 23 treatment-naïve patients with CRVO-CME. The best-corrected visual acuity (BCVA), letter contrast sensitivity (LCS), severity of metamorphopsia (M-CHARTS), amount of aniseikonia (New Aniseikonia Test), and stereopsis (Titmus Stereo Test and TNO stereotest) were examined every month from before treatment to 12 months after treatment. For VR-QoL assessment, the 25-item National Eye Institute Visual Function Questionnaire (VFQ-25) was provided to the patients before treatment and at 3, 6, and 12 months after treatment. Stepwise multiple regression analysis revealed that the BCVA of the fellow eye was related to the VFQ-25 composite score before treatment, and that the BCVA of the fellow eye and TNO values were related to the VFQ-25 composite score 12 months after treatment. Changes in LCS were significantly correlated with changes in the VFQ-25 composite score. In patients with CRVO-CME, visual acuity of the fellow eye had the strongest impact on VR-QoL. The contrast sensitivity of the affected eye and stereopsis were also associated with VR-QoL.